Gut Microbiota Profile Identifies Transition From Compensated Cardiac Hypertrophy to Heart Failure in Hypertensive Rats

Gutiérrez-Calabrés, Elena; Ortega‐Hernández, Adriana; Modrego, Javier; Gómez-Gordo, Rubén; Caro-Vadillo, Alicia; Rodríguez-Bobada, Cruz; González, Pablo; Gómez‐Garre, Dulcenombre

doi:10.1161/hypertensionaha.120.15123

Cited by 43 publications

(34 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For instence, Blautia were positively associated with T2D [ 69 ]. Ruminiclostridium_6 has been shown to be involved in enhancing inflammatory responses [ 70 ]. In our study, DSS treatment significantly increased the relative abundance of Blautia and Ruminiclostridum_6 in mice, which might be responsible for inducing colitis.…”

Section: Discussionmentioning

confidence: 99%

Taxifolin Alleviates DSS-Induced Ulcerative Colitis by Acting on Gut Microbiome to Produce Butyric Acid

Zhang

et al. 2022

Nutrients

View full text Add to dashboard Cite

Taxifolin is a bioflavonoid which has been used to treat Inflammatory Bowel Disease. However, taxifolin on DSS-induced colitis and gut health is still unclear. Here, we studied the effect of taxifolin on DSS-induced intestinal mucositis in mice. We measured the degree of intestinal mucosal injury and inflammatory response in DSS treated mice with or without taxifolin administration and studied the changes of fecal metabolites and intestinal microflora using 16S rRNA. The mechanism was further explored by fecal microbiota transplantation. The results showed that the weight loss and diarrhea score of the mice treated with taxifolin decreased in DSS-induced mice and longer colon length was displayed after taxifolin supplementation. Meanwhile, the expression of GPR41 and GPR43 in the colon was significantly increased by taxifolin treatment. Moreover, the expression of TNF-α, IL-1β, and IL-6 in colon tissue was inhibited by taxifolin treatment. The fecal metabolism pattern changed significantly after DSS treatment, which was reversed by taxifolin treatment. Importantly, taxifolin significantly increased the levels of butyric acid and isobutyric acid in the feces of DSS-treated mice. In terms of gut flora, taxifolin reversed the changes of Akkermansia, and further decreased uncultured_bacterium_f_Muribaculaceae. Fecal transplantation from taxifolin-treated mice showed a lower diarrhea score, reduced inflammatory response in the colon, and reduced intestinal mucosal damage, which may be related to the increased level of butyric acid in fecal metabolites. In conclusion, this study provides evidence that taxifolin can ameliorate DSS-induced colitis by altering gut microbiota to increase the production of SCFAs.

show abstract

Section: Discussionmentioning

confidence: 99%

Taxifolin Alleviates DSS-Induced Ulcerative Colitis by Acting on Gut Microbiome to Produce Butyric Acid

Zhang

et al. 2022

Nutrients

View full text Add to dashboard Cite

show abstract

“…Among the new fields that are opening in the pathophysiology of heart failure, the intestinal microbiota and some of its metabolites stand out [ 36 ]. In some models, Akkermansia , Prevotella 9 , Paraprevoltella , and Phascolarctobaterium have been associated with changes in cardiac structure and function [ 37 ]. The "intestinal hypothesis" of heart failure postulates that the reduction in cardiac output causes damage to the intestinal barrier that generates dysbiosis, favoring the proliferation of pathogenic species such as Candida and the reduction of anti-inflammatory bacteria such as Faecalibacterium prausnitzii.…”

Section: Pathophysiologymentioning

confidence: 99%

Heart Failure in Type 1 Diabetes: A Complication of Concern? A Narrative Review

Gómez-Pérez

Damas-Fuentes

Cornejo‐Pareja

et al. 2021

JCM

View full text Add to dashboard Cite

Heart failure (HF) has been a hot topic in diabetology in the last few years, mainly due to the central role of sodium-glucose cotransporter 2 inhibitors (iSGLT2) in the prevention and treatment of cardiovascular disease and heart failure. It is well known that HF is a common complication in diabetes. However, most of the knowledge about it and the evidence of cardiovascular safety trials with antidiabetic drugs refer to type 2 diabetes (T2D). The epidemiology, etiology, and pathophysiology of HF in type 1 diabetes (T1D) is still not well studied, though there are emerging data about it since life expectancy for T1D has increased in the last decades and there are more elderly patients with T1D. The association of T1D and HF confers a worse prognosis than in T2D, thus it is important to investigate the characteristics, risk factors, and pathophysiology of this disease in order to effectively design prevention strategies and therapeutic tools.

show abstract

“…Enterobacter and Paraprevotella were lower in the poor-controlled group. Enterobacter and Paraprevotella have been previously confirmed to be extremely elevated in hypertensive patients or animals ( Chang et al, 2020 ; Gutierrez-Calabres et al, 2020 ). In the well-controlled groups, the LDA scores revealed 19 biomarkers that were significantly different from the other groups ( Figure 3B ).…”

Section: Resultsmentioning

confidence: 96%

Antihypertensive Therapy by ACEI/ARB Is Associated With Intestinal Flora Alterations and Metabolomic Profiles in Hypertensive Patients

Dong

Wang

Jiao

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ACEI/ARB) are the first-line drugs for the treatment of essential hypertension (HTN), one of the most important risk factors for cardiovascular and cerebrovascular diseases. Intestinal flora and microbial metabolites have been demonstrated to play important roles in blood pressure (BP) regulation and HTN development. However, it remains elusive that intestinal bacteria and metabolites are associated with the protective effects of ACEI/ARB anti-hypertensive drugs against HTN. In this study, we evaluated the effect of ACEI/ARB on gut microbiome and metabolites in patients suffering from HTN. We performed 16S rRNA sequencing and fecal metabolomic analysis of 36 HTN patients placed on ACEI/ARB therapy and 19 newly diagnosed HTN patients with no history of anti-hypertensive treatment. Patients under medication treatment were further classified into well-controlled (n = 24) and poor-controlled (n = 12) groups according to their BP levels. The ACEI/ARB improved the intestinal microbiome of the HTN patients by reducing potentially pathogenic bacteria such as Enterobacter and Klebsiella and increasing beneficial bacteria such as Odoribacter. Moreover, ACEI/ARB therapy was correlated with significant metabolomic changes in the HTN patients, including progressively enhanced inositol from poor-controlled to well-controlled groups. The profiles of gut bacteria were linked to the production of metabolites, and inositol was negatively correlated with Klebsiella, Enterobacter, and Proteobacteria. Our study suggests that ACEI/ARB modulates gut microbial composition and functions and alters microbial metabolites in HTN patients.

show abstract

Gut Microbiota Profile Identifies Transition From Compensated Cardiac Hypertrophy to Heart Failure in Hypertensive Rats

Cited by 43 publications

References 24 publications

Taxifolin Alleviates DSS-Induced Ulcerative Colitis by Acting on Gut Microbiome to Produce Butyric Acid

Taxifolin Alleviates DSS-Induced Ulcerative Colitis by Acting on Gut Microbiome to Produce Butyric Acid

Heart Failure in Type 1 Diabetes: A Complication of Concern? A Narrative Review

Antihypertensive Therapy by ACEI/ARB Is Associated With Intestinal Flora Alterations and Metabolomic Profiles in Hypertensive Patients

Contact Info

Product

Resources

About